BNP Paribas Upgrades Phibro Animal Health (NASDAQ:PAHC) to Hold

BNP Paribas upgraded shares of Phibro Animal Health (NASDAQ:PAHC - Free Report) to a hold rating in a research report report published on Monday morning,Zacks.com reports.

A number of other brokerages have also recently commented on PAHC. BNP Paribas Exane raised Phibro Animal Health from an "underperform" rating to a "neutral" rating and set a $24.00 target price for the company in a report on Monday, June 16th. Wall Street Zen upgraded Phibro Animal Health from a "hold" rating to a "buy" rating in a research report on Friday, May 9th. Finally, Morgan Stanley upped their price target on Phibro Animal Health from $20.00 to $21.00 and gave the company an "equal weight" rating in a research report on Thursday, May 8th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and one has given a buy rating to the company's stock. According to MarketBeat, Phibro Animal Health currently has a consensus rating of "Hold" and an average target price of $20.80.

Phibro Animal Health Price Performance

Shares of Phibro Animal Health stock traded down $0.08 during mid-day trading on Monday, reaching $23.88. 247,450 shares of the stock traded hands, compared to its average volume of 207,387. The business has a 50-day moving average of $21.85 and a 200 day moving average of $21.92. Phibro Animal Health has a fifty-two week low of $16.16 and a fifty-two week high of $26.55. The stock has a market capitalization of $967.86 million, a PE ratio of 30.62, a PEG ratio of 0.45 and a beta of 0.74. The company has a quick ratio of 1.23, a current ratio of 2.91 and a debt-to-equity ratio of 2.67.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.63 EPS for the quarter, beating analysts' consensus estimates of $0.52 by $0.11. Phibro Animal Health had a return on equity of 30.51% and a net margin of 2.68%. The business had revenue of $347.80 million during the quarter, compared to analysts' expectations of $352.41 million. On average, analysts predict that Phibro Animal Health will post 1.95 EPS for the current year.

Phibro Animal Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 25th. Investors of record on Wednesday, June 4th will be given a $0.12 dividend. The ex-dividend date is Wednesday, June 4th. This represents a $0.48 annualized dividend and a yield of 2.01%. Phibro Animal Health's payout ratio is 61.54%.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Man Group plc purchased a new position in Phibro Animal Health in the fourth quarter worth approximately $501,000. GAMMA Investing LLC grew its position in Phibro Animal Health by 2,011.4% in the first quarter. GAMMA Investing LLC now owns 36,718 shares of the company's stock worth $784,000 after acquiring an additional 34,979 shares during the period. Lazard Asset Management LLC boosted its position in shares of Phibro Animal Health by 2,739.7% during the fourth quarter. Lazard Asset Management LLC now owns 1,647 shares of the company's stock worth $34,000 after buying an additional 1,589 shares during the period. Nuveen Asset Management LLC boosted its position in shares of Phibro Animal Health by 21.4% during the fourth quarter. Nuveen Asset Management LLC now owns 588,001 shares of the company's stock worth $12,348,000 after buying an additional 103,618 shares during the period. Finally, Alliancebernstein L.P. boosted its position in shares of Phibro Animal Health by 357.1% during the fourth quarter. Alliancebernstein L.P. now owns 130,000 shares of the company's stock worth $2,730,000 after buying an additional 101,560 shares during the period. 99.34% of the stock is currently owned by hedge funds and other institutional investors.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.